Gastrointestinal stromal tumours (GISTs) are mesenchymal neoplasms that arise in the
gastrointestinal tract, usually in the stomach or the small intestine and rarely elsewhere in …

Background The risk of recurrence of gastrointestinal stromal tumour (GIST) after surgery
needs to be estimated when considering adjuvant systemic therapy. We assessed …

Highlights•This clinical practice guideline provides key recommendations on the
management of gastrointestinal stromal tumours.•Recommendations have been agreed …

Gastrointestinal stromal tumours (GISTs) are rare tumours, with an estimated unadjusted
incidence of around 1/100 000/year [1]. This only covers clinically relevant GISTs, since, if …

Context Adjuvant imatinib administered for 12 months after surgery has improved recurrence-
free survival (RFS) of patients with operable gastrointestinal stromal tumor (GIST) compared …

Gastrointestinal stromal tumours (GISTs) are rare tumours, with an estimated unadjusted
incidence of around 1/100 000/year [1]. This only covers clinically relevant GISTs, since it is …

Gastrointestinal stromal tumors (GISTs) are potentially malignancies that can occur
anywhere in the digestive tract. Tyrosine kinase inhibitors (TKIs) such as imatinib have …

Gastrointestinal stromal tumor (GIST) is the most common malignant neoplasm of
mesenchymal origin. GIST spans a wide clinical spectrum that ranges from tumors with …

Purpose In 2004, we started an intergroup randomized trial of adjuvant imatinib versus no
further therapy after R0-R1 surgery patients with localized, high-or intermediate-risk GI …

Gastrointestinal stromal tumor has received a lot of attention over the last 10 years due to its
unique biologic behavior, clinicopathological features, molecular mechanisms, and …